Ultragenyx wins priority review for burosumab; Genfit raising €150M for PhIII NASH study

→ Ultragenyx $RARE and its partners at Kyowa Hakko Kirin landed a priority review for burosumab to treat pediatric and adult patients with X-Linked Hypophosphatemia. The accelerated PR gives them a shot at an April 17, 2018 PDUFA date.

→ Genfit (Euronext: GNFT) is raising €150 million so it can wrap up its Phase III for elafibranor in NASH and take the data to regulators.

→ France’s Biophytis has raised €10.4 million for mid-stage studies of its drugs for age-related diseases. The biotech is working on sarcopenia and age-related macular degeneration.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->